Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: Results from a Prospective Phase 2 Clinical Trial.

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 Health-related quality of life Radical surgery Short term Upper urinary tract Urothelial carcinoma

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Feb 2024
Historique:
accepted: 11 12 2023
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: epublish

Résumé

The possible negative impact of radical surgery on patients' health-related quality of life (HRQoL) plays an important role in preoperative counseling. Here, we analyzed the HRQoL of patients treated for upper urinary tract urothelial carcinoma (UTUC) in the context of a single-arm phase 2 multicenter study, in which the safety and efficacy of a single preoperative intravesical instillation with mitomycin C were investigated. Our objective was to investigate early changes in HRQoL in patients undergoing radical surgery for UTUC and identify factors associated with these outcomes. Patients with pTanyN0-1M0 UTUC were prospectively included. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire at baseline, and at 1 and 3 mo after surgery. A linear mixed model was used to evaluate the changes in HRQoL over time and identify the variables associated with these outcomes. The clinical effect size was used to assess the clinical impact and level of perceptibility of HRQoL changes for clinicians and/or patients based on given thresholds. Between 2017 and 2020, 186 patients were included. At baseline, 1 mo after surgery, and 3 mo after surgery, response rates were 91%, 84%, and 78%, respectively. One month after surgery, a statistically significant and clinically relevant deterioration was observed in physical, role, and social functioning, and for the included symptom scales: constipation, fatigue, and pain. An improvement in emotional functioning was observed. At 3 mo, HRQoL returned to baseline levels, except emotional functioning, which improved at 1 mo and persisted to be better than that before surgery. Age >70 yr was associated with worse physical functioning, but better social and emotional functioning. Male patients reported better emotional functioning than females. Postoperative complications were negatively associated with social functioning. UTUC patients treated with radical surgery experienced a significant, albeit temporary, decline in HRQoL. Three months following surgery, HRQoL outcomes returned to baseline levels. This information can be used to counsel UTUC patients before undergoing radical surgery and contextualize recovery after surgery. We investigated the changes in quality of life as reported by patients who underwent surgery for upper tract urothelial carcinoma (UTUC). We found that patients experienced a decline in quality of life 1 mo after surgery, but this was temporary, with full recovery of quality of life 3 mo after surgery. These findings can help doctors and other medical staff in counseling UTUC patients before undergoing radical surgery.

Sections du résumé

Background and objective UNASSIGNED
The possible negative impact of radical surgery on patients' health-related quality of life (HRQoL) plays an important role in preoperative counseling. Here, we analyzed the HRQoL of patients treated for upper urinary tract urothelial carcinoma (UTUC) in the context of a single-arm phase 2 multicenter study, in which the safety and efficacy of a single preoperative intravesical instillation with mitomycin C were investigated. Our objective was to investigate early changes in HRQoL in patients undergoing radical surgery for UTUC and identify factors associated with these outcomes.
Methods UNASSIGNED
Patients with pTanyN0-1M0 UTUC were prospectively included. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire at baseline, and at 1 and 3 mo after surgery. A linear mixed model was used to evaluate the changes in HRQoL over time and identify the variables associated with these outcomes. The clinical effect size was used to assess the clinical impact and level of perceptibility of HRQoL changes for clinicians and/or patients based on given thresholds.
Key findings and limitations UNASSIGNED
Between 2017 and 2020, 186 patients were included. At baseline, 1 mo after surgery, and 3 mo after surgery, response rates were 91%, 84%, and 78%, respectively. One month after surgery, a statistically significant and clinically relevant deterioration was observed in physical, role, and social functioning, and for the included symptom scales: constipation, fatigue, and pain. An improvement in emotional functioning was observed. At 3 mo, HRQoL returned to baseline levels, except emotional functioning, which improved at 1 mo and persisted to be better than that before surgery. Age >70 yr was associated with worse physical functioning, but better social and emotional functioning. Male patients reported better emotional functioning than females. Postoperative complications were negatively associated with social functioning.
Conclusions and clinical implications UNASSIGNED
UTUC patients treated with radical surgery experienced a significant, albeit temporary, decline in HRQoL. Three months following surgery, HRQoL outcomes returned to baseline levels. This information can be used to counsel UTUC patients before undergoing radical surgery and contextualize recovery after surgery.
Patient summary UNASSIGNED
We investigated the changes in quality of life as reported by patients who underwent surgery for upper tract urothelial carcinoma (UTUC). We found that patients experienced a decline in quality of life 1 mo after surgery, but this was temporary, with full recovery of quality of life 3 mo after surgery. These findings can help doctors and other medical staff in counseling UTUC patients before undergoing radical surgery.

Identifiants

pubmed: 38375344
doi: 10.1016/j.euros.2023.12.005
pii: S2666-1683(23)02536-3
pmc: PMC10874848
doi:

Types de publication

Journal Article

Langues

eng

Pagination

15-23

Informations de copyright

© 2023 The Author(s).

Auteurs

Thomas van Doeveren (T)

Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Sebastiaan Remmers (S)

Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Vera Atema (V)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.

Roderick C N van den Bergh (RCN)

Department of Urology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.

Egbert R Boevé (ER)

Department of Urology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands.

Erik B Cornel (EB)

Department of Urology, Ziekenhuis Groep Twente, Hengelo, The Netherlands.

Antoine G van der Heijden (AG)

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Kees Hendricksen (K)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Evelyne C C Cauberg (ECC)

Department of Urology, Isala Medical Center, Zwolle, The Netherlands.

Rens A L Jacobs (RAL)

Department of Urology, Zuyderland Medical Center, Heerlen and Sittard, The Netherlands.

Bin K Kroon (BK)

Department of Urology, Rijnstate Medical Center, Arnhem, The Netherlands.

Annemarie M Leliveld (AM)

Department of Urology, University Medical Center Groningen, Groningen, The Netherlands.

Richard P Meijer (RP)

Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands.

Bob Merks (B)

Department of Urology, Haaglanden Medical Center, Leidschendam, The Netherlands.

Jorg R Oddens (JR)

Department of Urology, AmsterdamUMC, University of Amsterdam, Amsterdam, The Netherlands.

Luc Roelofs (L)

Department of Urology, Treant Zorggroep, Emmen, The Netherlands.

Diederik M Somford (DM)

Department of Urology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.

Peter de Vries (P)

Department of Urology, Treant Zorggroep, Emmen, The Netherlands.

Bart Wijsman (B)

Department of Urology, Elisabeth-Tweesteden Medical Center, Tilburg, The Netherlands.

Willemijn A K M Windt (WAKM)

Department of Urology, Martini Ziekenhuis, Groningen, The Netherlands.

Peter J Zwaan (PJ)

Department of Urology, Gelre Ziekenhuis, Apeldoorn, The Netherlands.

Pim J van Leeuwen (PJ)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Joost L Boormans (JL)

Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Katja K H Aben (KKH)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.

Classifications MeSH